Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients

Applied Immunohistochemistry & Molecular Morphology : AIMM
Ling GuoEric D Hsi

Abstract

Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPD)/lymphomas in nonimmunosuppressed patients represent a unique entity and have been proposed to be related to immune senescence. Engagement of programmed cell death 1 (PD1) by its ligand programmed death ligand 1 (PDL1) inhibits T-cell activation, and leads to T-cell exhaustion. In clinical trials, therapeutic antibodies that block the PD1-PDL1 axis have shown promising therapeutic activity in certain types of lymphomas. Although PD1/PDL1 has been extensively studied in variety of lymphomas, there are few reports characterizing their expression in EBV-positive LPD. As these group of patients are presumed to be associated with immunosenescence/immune dysregulation, we hypothesize that the immune checkpoint pathway might be relevant in this entity. We explored the expression of PD1, PDL1 and its clinicopathologic association in 6 patients with a total of 8 independent specimens of EBV-positive LPD/lymphomas. We also applied proximity assay, a novel technique, which can identify intermolecular interaction, to evaluate physical interaction or in situ engagement of PD1 and PDL1. We found that the malignant cells in the EBV-positive LPDs express PDL1. PD1-positive ...Continue Reading

References

Apr 17, 2007·Current Opinion in Immunology·Mary E KeirArlene H Sharpe
Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takashi OyamaShigeo Nakamura
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
May 27, 2008·Nature Reviews. Immunology·Weiping Zou, Lieping Chen
Mar 21, 2013·British Journal of Cancer·S A Quezada, K S Peggs
May 16, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin J ChenScott J Rodig
Sep 28, 2014·Blood Reviews·Locke J Bryan, Leo I Gordon
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
May 20, 2015·Current Oncology Reports·Loretta J Nastoupil, Sattva S Neelapu
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe ArmandCraig H Moskowitz

❮ Previous
Next ❯

Citations

Jul 30, 2020·Minerva gastroenterologica e dietologica·Nicolò De PretisLuca Frulloni

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
Assay

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
R A DroeserLuigi Tornillo
Nihon rinsho. Japanese journal of clinical medicine
Yoshie ShimoyamaTakashi Oyama
© 2022 Meta ULC. All rights reserved